CEL-SCI (CVM) Competitors $0.25 0.00 (-1.05%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.26 +0.01 (+2.83%) As of 04/17/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CVM vs. ZURA, ANL, CRBU, XCUR, EPIX, UNCY, SGMT, ADAG, ADVM, and IGMSShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Zura Bio (ZURA), Adlai Nortye (ANL), Caribou Biosciences (CRBU), Exicure (XCUR), ESSA Pharma (EPIX), Unicycive Therapeutics (UNCY), Sagimet Biosciences (SGMT), Adagene (ADAG), Adverum Biotechnologies (ADVM), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Zura Bio Adlai Nortye Caribou Biosciences Exicure ESSA Pharma Unicycive Therapeutics Sagimet Biosciences Adagene Adverum Biotechnologies IGM Biosciences CEL-SCI (NYSE:CVM) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends. Is CVM or ZURA more profitable? Zura Bio's return on equity of -37.36% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% Zura Bio N/A -37.36%-29.81% Do insiders and institutionals hold more shares of CVM or ZURA? 12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 16.2% of CEL-SCI shares are held by insiders. Comparatively, 22.1% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, CVM or ZURA? CEL-SCI has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Which has stronger valuation & earnings, CVM or ZURA? Zura Bio is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$0.48-0.53Zura BioN/AN/A-$69.24M-$0.53-2.32 Do analysts prefer CVM or ZURA? Zura Bio has a consensus target price of $14.67, indicating a potential upside of 1,092.41%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the MarketBeat Community believe in CVM or ZURA? Zura Bio received 23 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 79.31% of users gave Zura Bio an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes23100.00% Zura BioOutperform Votes2379.31% Underperform Votes620.69% Does the media refer more to CVM or ZURA? In the previous week, Zura Bio had 1 more articles in the media than CEL-SCI. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for CEL-SCI. Zura Bio's average media sentiment score of 0.82 beat CEL-SCI's score of 0.00 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CEL-SCI 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryZura Bio beats CEL-SCI on 12 of the 16 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$20.41M$2.84B$5.30B$18.41BDividend YieldN/A1.86%5.45%4.20%P/E Ratio-0.5330.4821.8631.07Price / SalesN/A441.91380.5226.55Price / CashN/A168.6838.2617.53Price / Book1.703.466.454.30Net Income-$26.92M-$72.06M$3.22B$1.02B1 Month Performance-11.47%-16.75%-9.71%-8.22%1 Year Performance-83.67%-26.05%11.51%1.66% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCIN/A$0.25-1.0%N/A-83.2%$20.41MN/A-0.5343Gap UpZURAZura Bio2.105 of 5 stars$1.12-7.4%$14.67+1,209.5%-66.7%$76.58MN/A-2.113News CoverageANLAdlai Nortye1.5936 of 5 stars$2.08+7.0%$9.00+333.7%-83.9%$76.57M$5M0.00127Short Interest ↑News CoverageCRBUCaribou Biosciences2.2154 of 5 stars$0.80-8.5%$10.33+1,191.3%-81.2%$74.42M$9.99M-0.48100Analyst RevisionNews CoverageXCURExicure1.7775 of 5 stars$11.73+1.3%N/A+1,358.2%$74.11M$500,000.00-5.6750Short Interest ↓Gap UpEPIXESSA Pharma2.5805 of 5 stars$1.65+4.4%$9.50+475.8%-73.4%$73.24MN/A-2.3950Positive NewsUNCYUnicycive Therapeutics2.8221 of 5 stars$0.61+11.4%$5.25+760.7%-44.9%$73.02M$680,000.00-0.639Gap UpSGMTSagimet Biosciences2.1288 of 5 stars$2.38+3.0%$22.40+841.2%-44.3%$73.01M$2M-1.668Gap UpADAGAdagene2.5177 of 5 stars$1.52-0.7%$8.00+426.3%-42.0%$71.61M$103,204.000.00260Short Interest ↑Positive NewsADVMAdverum Biotechnologies3.8184 of 5 stars$3.43flat$27.83+711.5%-73.7%$71.35M$1M-0.57190Earnings ReportAnalyst ForecastNews CoverageIGMSIGM Biosciences3.1085 of 5 stars$1.19-0.8%$5.50+362.2%-83.5%$71.13M$2.68M-0.33190News Coverage Related Companies and Tools Related Companies Zura Bio Competitors Adlai Nortye Competitors Caribou Biosciences Competitors Exicure Competitors ESSA Pharma Competitors Unicycive Therapeutics Competitors Sagimet Biosciences Competitors Adagene Competitors Adverum Biotechnologies Competitors IGM Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CVM Stock Free CVM Stock Alerts